STOCK TITAN

Surmodics, Inc. - $SRDX STOCK NEWS

Welcome to our dedicated page for Surmodics news (Ticker: $SRDX), a resource for investors and traders seeking the latest updates and insights on Surmodics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Surmodics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Surmodics's position in the market.

Rhea-AI Summary
SRDX: Surmodics Reports Strong Financial Results and Fiscal 2024 Guidance, Announces New Product Launches and Clinical Trial Data
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.36%
Tags
-
Rhea-AI Summary
Surmodics, Inc. will present 24-month data from the SWING Trial, evaluating the Sundance™ Sirolimus Drug-Coated Balloon's safety and performance in treating occlusive lesions in the infra-popliteal arteries. The trial reports an 8.3% major adverse event rate at 6 months and an 80% target lesion primary patency rate at 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
Rhea-AI Summary
Surmodics, Inc. (NASDAQ:SRDX) announced that 36-month data from its TRANSCEND clinical trial will be presented at the 50th Annual VEITH Symposium. Dr. Peter A. Schneider will share the trial's safety and efficacy data in a session focused on randomized controlled trial updates on drug coated balloons and drug eluting stents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
Rhea-AI Summary
Surmodics, Inc. has launched Preside hydrophilic coatings, its most advanced medical device coating technology. The coatings offer low-friction and low-particulate generation, improving distal access for neurovascular applications and crossing for challenging coronary lesions. The coatings are formulated to balance enhanced lubricity and coating durability. Surmodics has secured the first 510(k) device clearance for this technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
none
-
Rhea-AI Summary
Surmodics, Inc. to release Q4 2023 financial results on November 8
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
conferences
Rhea-AI Summary
Surmodics, Inc. (SRDX) reported a total revenue of $52.5 million, a 111% increase year-over-year, with a GAAP Diluted EPS of $0.52. The company obtained FDA premarket approval for the SurVeil DCB, leading to a $27 million milestone payment, and received FDA 510(k) clearance for its Pounce LP Thrombectomy System. Medical Device revenue grew by 163%, while In Vitro Diagnostics revenue decreased by 12%. Surmodics now expects fiscal year 2023 total revenue to range from $130 million to $132 million, representing an increase of 30% to 32% compared to the prior year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.05%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.11%
Tags
Surmodics, Inc.

Nasdaq:SRDX

SRDX Rankings

SRDX Stock Data

478.57M
10.61M
3.75%
91.43%
3.14%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
EDEN PRAIRIE

About SRDX

surmodics partners with the world's leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. following two recent acquisitions, the company is transforming its medical device business from being a provider of coating technologies, to offering whole-product solutions. throughout its transformation, surmodics’ mission remains: to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges.